Market Research Logo

Analgesics Market: North America to Remain Largest Revenue Market Throughout the Forecast Period: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

Analgesics Market: North America to Remain Largest Revenue Market Throughout the Forecast Period: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

This Future Market Insights (FMI) report examines the ‘Global Analgesics Market’ for the period 2018–2028. The primary objective of the report is to offer updates and information related to market opportunities in the global analgesics market.

The Analgesics Market is Segmented Based on:

Drug Class

Pain Type

Distribution Channel

Region

This report covers the global analgesics market performance in terms of revenue contribution from various segments. The global analgesics market report begins with an overview and its definitions. The market viewpoints section underlines macro-economic factors influencing the growth of the global analgesics market along with detailing the opportunity analysis of the market. This is then followed by the key market drivers, restraints and trends.

When considering the analgesics market, it is split by prescription and over-the-counter (OTC) analgesics. Each segment of the global analgesics market is tracked by prescription and OTC revenue generation.

By drug class, the global analgesics market is segmented as opioids, non-steroidal anti-inflammatory drugs (NSAIDs), local anaesthetics and acetaminophen. The drug class segment is analysed by both prescription analgesics and OTC analgesics. Opioids is expected to remain the dominant segment due to their higher efficacy in pain management. The premium price of opioid also helps it to generate more revenue as compared to other types of analgesics. The adoption of opioid analgesics is higher in North America and Western Europe due to reimbursements and easy availability. Whereas, NSAIDs analgesics are highly adopted in Asia-Pacific, Eastern Europe and Latin America.

By pain type, the global analgesics market is segmented as surgical pain, cancer pain, neuropathic pain and other types of pain. The surgical pain is expected to be the dominant segment in the global analgesics market followed by cancer pain and neuropathic pain, respectively. This segment is also split into prescription analgesics and OTC analgesics.

By distribution channel, the global analgesics market is segmented into hospital pharmacies, retail pharmacies, drug stores, clinics and others. This considers revenue generation by prescription analgesics and OTC analgesics separately.

By region, the global analgesics market has been segmented into North America (the U.S. & Canada), Latin America (Brazil, Mexico, and Rest of Latin America), Western Europe (Germany, France, the U.K., Italy, Spain and Rest of Western Europe), Eastern Europe (Russia, Poland and Rest of Eastern Europe), Asia Pacific excluding China and Japan (India, Australia & New Zealand and Rest of Asia Pacific), China, Japan and Middle East and Africa (GCC Countries, South Africa and Rest of MEA). Each country and region in the report provides revenue generation by prescription analgesics and OTC analgesics within the forecast period.

A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index. The forecast of the analgesics market by country, drug class, pain type and distribution channel is represented in a tabular form for each region. This section will help to understand the present scenario and opportunity of the analgesics market in major countries by each segment.

In the next section of the report, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view of the key competitor firms in order to access the key differentiators among the competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to a market segment. The detailed profiles of players operating in the analgesics market are also provided in the report, which highlight company description, product/segment overview, SWOT analysis, financial information, key developments related to the analgesics market and the strategic overview.

The next section of the report highlights the market outlook for 2018–2028 and sets the forecast within the context of the analgesics market by region.

The above sections – by drug class, pain type and distribution channel – evaluate the historic market analysis and growth prospects of the analgesics market for the period 2018–2028. We have considered 2017 as the base year and provided data for the forecast period.

The final section of the report represents the global scenario of the analgesics market along with y-o-y growth and market forecast till 2028. This section also evaluates the global market opportunity over the forecast period as well as the absolute dollar opportunity for each year. This section will help to understand the overall market growth for analgesics and the opportunity analysis for every year over the forecast period.

To arrive at the market size, bottom-up approach is used to validate the total market size obtained for the analgesics market. The forecast presented in the report provides total revenue of the analgesics market over 2018–2028. FMI uses the triangulation methodology, which is primarily based on experimental techniques such as patient-level data to obtain precise market estimations for the analgesics market and insights on specific country/regions. The country-specific data is again analysed to derive data at a regional level and then at a global level. This methodology ensures high quality and accuracy of information.

The factors considered while developing the estimates of the analgesics market are epidemiology, treatment seeking rate, ratio of population prescribed with different analgesics.

On the other hand, FMI has also analysed the market by considering the revenue from the key players operating in the market. The key players are segmented at a Tier-level with respect to their revenues, product portfolio and geographical presence. This process involves analysis of annual reports of various companies, investor presentations, SEC filings, 10k reports, earning call transcripts and press releases. This task is done to fetch substantial information about the key players, their respective revenues and estimate their respective market share.

The revenue growth of the key market players is analysed over the historical period and qualitative assessment of new product launches and innovations has been made in order to validate and align the resultant market numbers. The market structure is closely studied and analysed at a regional level to map and ascertain incremental $ opportunity for companies, for instance, supply from domestic/regional players, small-scale enterprises or unorganized segments is also taken into consideration to arrive at the final market numbers.

While forecasting the market size for the analgesics market, we have considered the impact of several factors such as per capital healthcare expenditure, disposable income, new analgesics and approvals for new advanced analgesics, penetration of analgesics through various distribution channels, and generic penetration across all regions, among others. However, quantifying the analgesics market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the analgesics market and to identify the right growth opportunities in the global analgesics market


1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Analgesics Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Trends
5. Global Economic Outlook
5.1. Gross Domestic Product by Region & Country, 2006 – 2021
6. Key Inclusions
6.1. PEST Analysis
6.2. Key Regulations: Opioids
6.3. Opioid Consumption : Fast Fact
7. North America Analgesics Market Analysis 2013–2017 and Forecast 2018–2028
7.1. Introduction
7.2. Historical Market Value (US$ Mn) Analysis By Country, 2013–2017
7.2.1. U.S.
7.2.2. Canada
7.3. Market Value (US$ Mn) Forecast By Country, 2018–2028
7.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2013–2017
7.4.1. Opioids
7.4.2. NSAIDs
7.4.3. Local Anesthetics
7.4.4. Acetaminophen
7.5. Market Value (US$ Mn) Forecast By Drug Class, 2018–2028
7.6. Historical Market Value (US$ Mn) Trend Analysis By Pain Type, 2013–2017
7.6.1. Surgical Pain
7.6.2. Cancer Pain
7.6.3. Neuropathic Pain
7.6.4. Others
7.7. Market Value (US$ Mn) Forecast By Pain Type, 2018–2028
7.8. Historical Market Value (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
7.8.1. Injectable
7.8.2. Oral
7.8.3. Topical
7.8.4. Transdermal
7.8.5. Others
7.9. Market Value (US$ Mn) Forecast By Route of Administration, 2018–2028
7.10.Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
7.10.1. Hospital Pharmacies
7.10.2. Retail Pharmacies
7.10.3. Drug Store
7.10.4. Clinics
7.10.5. Others
7.11.Market Value (US$ Mn) Forecast By Distribution Channel, 2018–2028
7.12.Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Drug Class
7.12.3. By Pain Type
7.12.4. By Route of Administration
7.12.5. By Distribution Channel
7.13.Drivers and Restraints – Impact Analysis
8. Western Europe Analgesics Market Analysis 2013–2017 and Forecast 2018–2028
8.1. Introduction
8.2. Historical Market Value (US$ Mn) By Country, 2013–2017
8.2.1. Germany
8.2.2. France
8.2.3. U.K.
8.2.4. Spain
8.2.5. Italy
8.2.6. Rest of Western Europe
8.3. Market Value (US$ Mn) Forecast By Country, 2018–2028
8.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2013–2017
8.4.1. Opioids
8.4.2. NSAIDs
8.4.3. Local Anesthetics
8.4.4. Acetaminophen
8.5. Market Value (US$ Mn) Forecast By Drug Class, 2018–2028
8.6. Historical Market Value (US$ Mn) Trend Analysis By Pain Type, 2013–2017
8.6.1. Surgical Pain
8.6.2. Cancer Pain
8.6.3. Neuropathic Pain
8.6.4. Others
8.7. Market Value (US$ Mn) Forecast By Pain Type, 2018–2028
8.8. Historical Market Value (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
8.8.1. Injectable
8.8.2. Oral
8.8.3. Topical
8.8.4. Transdermal
8.8.5. Others
8.9. Market Value (US$ Mn) Forecast By Route of Administration, 2018–2028
8.10.Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
8.10.1. Hospital Pharmacies
8.10.2. Retail Pharmacies
8.10.3. Drug Store
8.10.4. Clinics
8.10.5. Others
8.11.Market Value (US$ Mn) Forecast By Distribution Channel, 2018–2028
8.12.Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Drug Class
8.12.3. By Pain Type
8.12.4. By Route of Administration
8.12.5. By Distribution Channel
8.13.Drivers and Restraints – Impact Analysis
9. Eastern Europe Analgesics Market Analysis 2013–2017 and Forecast 2018–2028
9.1. Introduction
9.2. Historical Market Value (US$ Mn) By Country, 2013–2017
9.2.1. Russia
9.2.2. Poland
9.2.3. Rest of Eastern Europe
9.3. Market Value (US$ Mn) Forecast By Country, 2018–2028
9.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2013–2017
9.4.1. Opioids
9.4.2. NSAIDs
9.4.3. Local Anesthetics
9.4.4. Acetaminophen
9.5. Market Value (US$ Mn) Forecast By Drug Class, 2018–2028
9.6. Historical Market Value (US$ Mn) Trend Analysis By Pain Type, 2013–2017
9.6.1. Surgical Pain
9.6.2. Cancer Pain
9.6.3. Neuropathic Pain
9.6.4. Others
9.7. Market Value (US$ Mn) Forecast By Pain Type, 2018–2028
9.8. Historical Market Value (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
9.8.1. Injectable
9.8.2. Oral
9.8.3. Topical
9.8.4. Transdermal
9.8.5. Others
9.9. Market Value (US$ Mn) Forecast By Route of Administration, 2018–2028
9.10.Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
9.10.1. Hospital Pharmacies
9.10.2. Retail Pharmacies
9.10.3. Drug Store
9.10.4. Clinics
9.10.5. Others
9.11.Market Value (US$ Mn) Forecast By Distribution Channel, 2018–2028
9.12.Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Drug Class
9.12.3. By Pain Type
9.12.4. By Route of Administration
9.12.5. By Distribution Channel
9.13.Drivers and Restraints – Impact Analysis
10. Latin America Analgesics Market Analysis 2013–2017 and Forecast 2018–2028
10.1.Introduction
10.2.Historical Market Value (US$ Mn) By Country, 2013–2017
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3.Market Value (US$ Mn) Forecast By Country, 2018–2028
10.4.Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2013–2017
10.4.1. Opioids
10.4.2. NSAIDs
10.4.3. Local Anesthetics
10.4.4. Acetaminophen
10.5.Market Value (US$ Mn) Forecast By Drug Class, 2018–2028
10.6.Historical Market Value (US$ Mn) Trend Analysis By Pain Type, 2013–2017
10.6.1. Surgical Pain
10.6.2. Cancer Pain
10.6.3. Neuropathic Pain
10.6.4. Others
10.7.Market Value (US$ Mn) Forecast By Pain Type, 2018–2028
10.8.Historical Market Value (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
10.8.1. Injectable
10.8.2. Oral
10.8.3. Topical
10.8.4. Transdermal
10.8.5. Others
10.9.Market Value (US$ Mn) Forecast By Route of Administration, 2018–2028
10.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Drug Store
10.10.4. Clinics
10.10.5. Others
10.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2018–2028
10.12. Market Attractiveness Analysis
10.12.1. By Country
10.12.2. By Drug Class
10.12.3. By Pain Type
10.12.4. By Route of Administration
10.12.5. By Distribution Channel
10.13. Drivers and Restraints – Impact Analysis
11. Asia Pacific excluding Japan and China (APEJC) Analgesics Market Analysis 2013–2017 and Forecast 2018–2028
11.1.Introduction
11.2.Historical Market Value (US$ Mn) By Country, 2013–2017
11.2.1. India
11.2.2. Australia and New Zealand
11.2.3. Rest of APEJC
11.3.Market Value (US$ Mn) Forecast By Country, 2018–2028
11.4.Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2013–2017
11.4.1. Opioids
11.4.2. NSAIDs
11.4.3. Local Anesthetics
11.4.4. Acetaminophen
11.5.Market Value (US$ Mn) Forecast By Drug Class, 2018–2028
11.6.Historical Market Value (US$ Mn) Trend Analysis By Pain Type, 2013–2017
11.6.1. Surgical Pain
11.6.2. Cancer Pain
11.6.3. Neuropathic Pain
11.6.4. Others
11.7.Market Value (US$ Mn) Forecast By Pain Type, 2018–2028
11.8.Historical Market Value (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
11.8.1. Injectable
11.8.2. Oral
11.8.3. Topical
11.8.4. Transdermal
11.8.5. Others
11.9.Market Value (US$ Mn) Forecast By Route of Administration, 2018–2028
11.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Drug Store
11.10.4. Clinics
11.10.5. Others
11.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2018–2028
11.12. Market Attractiveness Analysis
11.12.1. By Country
11.12.2. By Drug Class
11.12.3. By Pain Type
11.12.4. By Route of Administration
11.12.5. By Distribution Channel
11.13. Drivers and Restraints – Impact Analysis
12. Japan Analgesics Market Analysis 2013–2017 and Forecast 2018–2028
12.1.Introduction
12.2.Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2013–2017
12.2.1. Opioids
12.2.2. NSAIDs
12.2.3. Local Anesthetics
12.2.4. Acetaminophen
12.3.Market Value (US$ Mn) Forecast By Drug Class, 2018–2028
12.4.Historical Market Value (US$ Mn) Trend Analysis By Pain Type, 2013–2017
12.4.1. Surgical Pain
12.4.2. Cancer Pain
12.4.3. Neuropathic Pain
12.4.4. Others
12.5.Market Value (US$ Mn) Forecast By Pain Type, 2018–2028
12.6.Historical Market Value (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
12.6.1. Injectable
12.6.2. Oral
12.6.3. Topical
12.6.4. Transdermal
12.6.5. Others
12.7.Market Value (US$ Mn) Forecast By Route of Administration, 2018–2028
12.8.Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Drug Store
12.8.4. Clinics
12.8.5. Others
12.9.Market Value (US$ Mn) Forecast By Distribution Channel, 2018–2028
12.10. Market Attractiveness Analysis
12.10.1. By Drug Class
12.10.2. By Pain Type
12.10.3. By Route of Administration
12.10.4. By Distribution Channel
12.11. Drivers and Restraints – Impact Analysis
13. China Analgesics Market Analysis 2013–2017 and Forecast 2018–2028
13.1.Introduction
13.2.Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2013–2017
13.2.1. Opioids
13.2.2. NSAIDs
13.2.3. Local Anesthetics
13.2.4. Acetaminophen
13.3.Market Value (US$ Mn) Forecast By Drug Class, 2018–2028
13.4.Historical Market Value (US$ Mn) Trend Analysis By Pain Type, 2013–2017
13.4.1. Surgical Pain
13.4.2. Cancer Pain
13.4.3. Neuropathic Pain
13.4.4. Others
13.5.Market Value (US$ Mn) Forecast By Pain Type, 2018–2028
13.6.Historical Market Value (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
13.6.1. Injectable
13.6.2. Oral
13.6.3. Topical
13.6.4. Transdermal
13.6.5. Others
13.7.Market Value (US$ Mn) Forecast By Route of Administration, 2018–2028
13.8.Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Drug Store
13.8.4. Clinics
13.8.5. Others
13.9.Market Value (US$ Mn) Forecast By Distribution Channel, 2018–2028
13.10. Market Attractiveness Analysis
13.10.1. By Drug Class
13.10.2. By Pain Type
13.10.3. By Route of Administration
13.10.4. By Distribution Channel
13.11. Drivers and Restraints – Impact Analysis
14. MEA Analgesics Market Analysis 2013–2017 and Forecast 2018–2028
14.1.Introduction
14.2.Historical Market Value (US$ Mn) By Country, 2013–2017
14.2.1. GCC Countries
14.2.2. South Africa
14.2.3. Rest of MEA
14.3.Market Value (US$ Mn) Forecast By Country, 2018–2028
14.4.Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2013–2017
14.4.1. Opioids
14.4.2. NSAIDs
14.4.3. Local Anesthetics
14.4.4. Acetaminophen
14.5.Market Value (US$ Mn) Forecast By Drug Class, 2018–2028
14.6.Historical Market Value (US$ Mn) Trend Analysis By Pain Type, 2013–2017
14.6.1. Surgical Pain
14.6.2. Cancer Pain
14.6.3. Neuropathic Pain
14.6.4. Others
14.7.Market Value (US$ Mn) Forecast By Pain Type, 2018–2028
14.8.Historical Market Value (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
14.8.1. Injectable
14.8.2. Oral
14.8.3. Topical
14.8.4. Transdermal
14.8.5. Others
14.9.Market Value (US$ Mn) Forecast By Route of Administration, 2018–2028
14.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Drug Store
14.10.4. Clinics
14.10.5. Others
14.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2018–2028
14.12. Market Attractiveness Analysis
14.12.1. By Country
14.12.2. By Drug Class
14.12.3. By Pain Type
14.12.4. By Route of Administration
14.12.5. By Distribution Channel
14.13. Drivers and Restraints – Impact Analysis
15. Forecast Factors: Relevance and Impact
16. Forecast Assumptions
17. Competition Analysis
17.1.Competition Dashboard
17.2.Market Structure
17.3.Company Deep Dive
17.3.1. Teva Pharmaceutical Industries Ltd
17.3.1.1. Overview
17.3.1.2. Product and Application Portfolio
17.3.1.3. Production Footprint
17.3.1.4. Sales Footprint
17.3.1.5. Channel Footprint
17.3.1.6. Strategy
17.3.1.6.1. Marketing Strategy
17.3.1.6.2. Product Strategy
17.3.1.6.3. Channel Strategy
17.3.2. Novartis AG
17.3.2.1. Overview
17.3.2.2. Product and Application Portfolio
17.3.2.3. Production Footprint
17.3.2.4. Sales Footprint
17.3.2.5. Channel Footprint
17.3.2.6. Strategy
17.3.2.6.1. Marketing Strategy
17.3.2.6.2. Product Strategy
17.3.2.6.3. Channel Strategy
17.3.3. Allergan plc
17.3.3.1. Overview
17.3.3.2. Product and Application Portfolio
17.3.3.3. Production Footprint
17.3.3.4. Sales Footprint
17.3.3.5. Channel Footprint
17.3.3.6. Strategy
17.3.3.6.1. Marketing Strategy
17.3.3.6.2. Product Strategy
17.3.3.6.3. Channel Strategy
17.3.4. Pfizer Inc.
17.3.4.1. Overview
17.3.4.2. Product and Application Portfolio
17.3.4.3. Production Footprint
17.3.4.4. Sales Footprint
17.3.4.5. Channel Footprint
17.3.4.6. Strategy
17.3.4.6.1. Marketing Strategy
17.3.4.6.2. Product Strategy
17.3.4.6.3. Channel Strategy
17.3.5. Mylan N.V
17.3.5.1. Overview
17.3.5.2. Product and Application Portfolio
17.3.5.3. Production Footprint
17.3.5.4. Sales Footprint
17.3.5.5. Channel Footprint
17.3.5.6. Strategy
17.3.5.6.1. Marketing Strategy
17.3.5.6.2. Product Strategy
17.3.5.6.3. Channel Strategy
17.3.6. Egalet Corporation
17.3.6.1. Overview
17.3.6.2. Product and Application Portfolio
17.3.6.3. Production Footprint
17.3.6.4. Sales Footprint
17.3.6.5. Channel Footprint
17.3.6.6. Strategy
17.3.6.6.1. Marketing Strategy
17.3.6.6.2. Product Strategy
17.3.6.6.3. Channel Strategy
17.3.7. Pacira Pharmaceuticals
17.3.7.1. Overview
17.3.7.2. Product and Application Portfolio
17.3.7.3. Production Footprint
17.3.7.4. Sales Footprint
17.3.7.5. Channel Footprint
17.3.7.6. Strategy
17.3.7.6.1. Marketing Strategy
17.3.7.6.2. Product Strategy
17.3.7.6.3. Channel Strategy
17.3.8. Purdue Pharma L.P
17.3.8.1. Overview
17.3.8.2. Product and Application Portfolio
17.3.8.3. Production Footprint
17.3.8.4. Sales Footprint
17.3.8.5. Channel Footprint
17.3.8.6. Strategy
17.3.8.6.1. Marketing Strategy
17.3.8.6.2. Product Strategy
17.3.8.6.3. Channel Strategy
17.3.9. Endo International plc
17.3.9.1. Overview
17.3.9.2. Product and Application Portfolio
17.3.9.3. Production Footprint
17.3.9.4. Sales Footprint
17.3.9.5. Channel Footprint
17.3.9.6. Strategy
17.3.9.6.1. Marketing Strategy
17.3.9.6.2. Product Strategy
17.3.9.6.3. Channel Strategy
17.3.10. Janssen Pharmaceuticals, Inc.
17.3.10.1. Overview
17.3.10.2. Product and Application Portfolio
17.3.10.3. Production Footprint
17.3.10.4. Sales Footprint
17.3.10.5. Channel Footprint
17.3.10.6. Strategy
17.3.10.6.1. Marketing Strategy
17.3.10.6.2. Product Strategy
17.3.10.6.3. Channel Strategy
18. Global Analgesics Market Analysis 2013–2017 and Forecast 2018–2028, By Region
18.1.Introduction / Key Findings
18.2.Historical Market Size (US$ Mn) Trend Analysis By Region, 2013–2017
18.2.1. North America
18.2.2. Western Europe
18.2.3. Eastern Europe
18.2.4. Latin America
18.2.5. Asia Pacific excluding Japan and China
18.2.6. Japan
18.2.7. China
18.2.8. Middle East and Africa
18.3.Market Size (US$ Mn) Forecast By Region, 2018–2028
18.4.Market Attractiveness Analysis By Region
19. Global Analgesics Market Analysis 2013–2017 and Forecast 2018–2028, By Drug Class
19.1.Introduction
19.2.Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2013–2017
19.2.1. Opioids
19.2.2. NSAIDs
19.2.3. Local Anesthetics
19.2.4. Acetaminophen
19.3.Market Value (US$ Mn) Forecast By Drug Class, 2018–2028
19.4.Market Attractiveness Analysis By Drug Class
20. Global Analgesics Market Analysis 2013–2017 and Forecast 2018–2028, By Pain Type
20.1.Introduction
20.2.Historical Market Value (US$ Mn) Trend Analysis By Pain Type, 2013–2017
20.2.1. Surgical Pain
20.2.2. Cancer Pain
20.2.3. Neuropathic Pain
20.2.4. Others
20.3.Market Value (US$ Mn) Forecast By Pain Type, 2018–2028
20.4. Market Attractiveness Analysis By Pain Type
21. Global Analgesics Market Analysis 2013–2017 and Forecast 2018–2028, By Route of Administration
21.1.Introduction
21.2.Historical Market Value (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
21.2.1. Injectable
21.2.2. Oral
21.2.3. Topical
21.2.4. Transdermal
21.2.5. Others
21.3.Market Value (US$ Mn) Forecast By Route of Administration, 2018–2028
21.4. Market Attractiveness Analysis By Route of Administration
22. Global Analgesics Market Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
22.1.Introduction
22.2.Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
22.2.1. Hospital Pharmacies
22.2.2. Retail Pharmacies
22.2.3. Drug Store
22.2.4. Clinics
22.2.5. Others
22.3.Market Value (US$ Mn) Forecast By Distribution Channel, 2018–2028
22.4.Market Attractiveness Analysis By Distribution Channel
23. Global Analgesics Market Analysis 2013–2017 and Forecast 2018–2028
23.1.Market Value Share Analysis
23.2.Y-o-Y Growth Analysis
23.3.Absolute $ Opportunity
24. Research Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report